WO2006086454A3 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms - Google Patents

Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms Download PDF

Info

Publication number
WO2006086454A3
WO2006086454A3 PCT/US2006/004397 US2006004397W WO2006086454A3 WO 2006086454 A3 WO2006086454 A3 WO 2006086454A3 US 2006004397 W US2006004397 W US 2006004397W WO 2006086454 A3 WO2006086454 A3 WO 2006086454A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
life span
cells
organisms
increasing
Prior art date
Application number
PCT/US2006/004397
Other languages
French (fr)
Other versions
WO2006086454A2 (en
Inventor
David A Sinclair
Kevin J Bitterman
Original Assignee
Harvard College
David A Sinclair
Kevin J Bitterman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, David A Sinclair, Kevin J Bitterman filed Critical Harvard College
Priority to JP2007554337A priority Critical patent/JP2008529502A/en
Priority to EP06734562A priority patent/EP1851240B1/en
Priority to CA2595495A priority patent/CA2595495C/en
Priority to AU2006212770A priority patent/AU2006212770B2/en
Priority to ES06734562T priority patent/ES2401342T3/en
Publication of WO2006086454A2 publication Critical patent/WO2006086454A2/en
Publication of WO2006086454A3 publication Critical patent/WO2006086454A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Abstract

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPTl, PNCl, NMAl and NMA2. Another method comprises
PCT/US2006/004397 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms WO2006086454A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007554337A JP2008529502A (en) 2005-02-08 2006-02-08 Methods and compositions for extending cell and organism life and increasing stress tolerance
EP06734562A EP1851240B1 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2595495A CA2595495C (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
AU2006212770A AU2006212770B2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
ES06734562T ES2401342T3 (en) 2005-02-08 2006-02-08 Methods and compositions to prolong the period of life and increase the resistance to stress of cells and organisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/053,185 US7977049B2 (en) 2002-08-09 2005-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US11/053,185 2005-02-08

Publications (2)

Publication Number Publication Date
WO2006086454A2 WO2006086454A2 (en) 2006-08-17
WO2006086454A3 true WO2006086454A3 (en) 2007-03-29

Family

ID=36591266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/004397 WO2006086454A2 (en) 2005-02-08 2006-02-08 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Country Status (7)

Country Link
US (2) US7977049B2 (en)
EP (1) EP1851240B1 (en)
JP (3) JP2008529502A (en)
AU (1) AU2006212770B2 (en)
CA (1) CA2595495C (en)
ES (1) ES2401342T3 (en)
WO (1) WO2006086454A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421269A1 (en) * 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20090117543A1 (en) * 2004-05-04 2009-05-07 President And Fellows Of Harvard College Methods and compositions for inducing sirtuins
PT3006040T (en) * 2004-06-04 2018-03-28 Univ Washington Methods and compositions for treating neuropathies
ZA200701725B (en) * 2004-09-24 2008-06-25 Bayer Bioscience Nv Stress resistant plants
US20060276393A1 (en) * 2005-01-13 2006-12-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2007084162A2 (en) * 2005-04-08 2007-07-26 President And Fellows Of Harvard College Sirtuin inhibiting compounds
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP3730507A1 (en) * 2005-11-18 2020-10-28 Cornell Research Foundation, Inc. Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
AU2007229005B2 (en) * 2006-03-21 2012-05-31 Bayer Cropscience Nv Stress resistant plants
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
AU2008210327B2 (en) * 2007-01-31 2011-06-16 Methylation Sciences International Srl Extended release pharmaceutical formulations of S-adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008095056A2 (en) * 2007-02-01 2008-08-07 The Wistar Institute Method for identifying a compound that modulates sir2 protein activity
EP2214698A2 (en) * 2007-10-23 2010-08-11 President and Fellows of Harvard College Use of compounds activating sirt-3 for mimicking exercise
JP2011505149A (en) * 2007-11-30 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Industrial production method of organic compounds using a recombinant organism expressing a halogenated methyltransferase
JP5570731B2 (en) * 2008-02-28 2014-08-13 旭化成ファーマ株式会社 Method for measuring pyrophosphate
US20100173024A1 (en) * 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
BR112012001351A2 (en) 2009-07-22 2015-09-01 Univ California Method, genetically engineered yeast cell, and bacteria-yeast co-culture.
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
GB201007197D0 (en) * 2010-04-30 2010-06-16 Ge Healthcare Uk Ltd Methods and kits for determining the toxicity of an agent
AU2011274787B2 (en) 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9072766B2 (en) * 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
EP3345901A3 (en) * 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
WO2014059031A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
CA2928656C (en) * 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
TWI638047B (en) 2014-04-09 2018-10-11 史基普研究協會 Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
RU2016149764A (en) 2014-06-02 2018-07-17 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед PRODUCTION AND APPLICATION OF CRYSTAL BETA-D-NICOTINAMIDE RIBOSIDE
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US9995758B1 (en) * 2014-10-31 2018-06-12 Western Autotroph Company LLC Methods and systems for controlling oxidative stress in humans and animals
PL3268379T3 (en) 2015-03-09 2024-03-18 W.R. Grace & Co. - Conn. Crystalline form of nicotinamide riboside
US10603334B2 (en) 2015-04-28 2020-03-31 NewSouth Innovation Pty. Limited Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
WO2016178944A1 (en) 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
EP3288531B1 (en) * 2015-05-01 2019-07-24 The Procter and Gamble Company Method of improving skin health and compositions therefor
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US20160374908A1 (en) 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
DK3331894T3 (en) 2015-08-05 2021-03-22 Metro Int Biotech Llc NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USES THEREOF
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN112315837B (en) 2016-01-11 2021-12-03 宝洁公司 Methods of treating skin conditions and compositions therefor
EP3436469B1 (en) * 2016-03-31 2022-01-05 Berkeley Lights, Inc. Nucleic acid stabilization reagent, kits, and methods of use thereof
MX2018012849A (en) 2016-04-20 2019-08-29 Chromadex Inc Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors.
NZ753674A (en) 2016-11-11 2024-01-26 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US20190350960A1 (en) 2017-01-04 2019-11-21 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
TWI757528B (en) 2017-08-03 2022-03-11 美商欣爍克斯公司 Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
JP2021530447A (en) 2018-07-03 2021-11-11 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company How to treat skin condition
AU2020218203A1 (en) 2019-02-06 2021-08-26 Synthorx, Inc. IL-2 conjugates and methods of use thereof
US11491175B2 (en) 2019-02-25 2022-11-08 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
JP2022544776A (en) * 2019-08-14 2022-10-21 メトロ インターナショナル バイオテック，エルエルシー Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
CN110973260A (en) * 2019-12-11 2020-04-10 杨力 Nicotinamide riboside-containing milk and preparation method and application thereof
CN111394268B (en) * 2019-12-20 2021-06-18 合肥康诺生物制药有限公司 Genetically engineered bacterium, construction method and application thereof, and NAD (nicotinamide adenine dinucleotide) production+Method (2)
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2022032135A1 (en) * 2020-08-07 2022-02-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Single nucleotide polymorphisms and treatment of inflammatory conditions
EP4346842A1 (en) 2021-05-27 2024-04-10 Metro International Biotech, LLC Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
WO2023086770A1 (en) * 2021-11-10 2023-05-19 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection gene therapy
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179937A (en) 1978-06-02 1979-12-25 Ocean Ecology Ltd. Sound measuring device
FR2543550B1 (en) * 1983-04-01 1985-08-09 Cortial NOVEL TETRAHYDROXY-3 ', 4', 5.7 FLAVONE DERIVATIVES, THEIR PREPARATION METHOD AND THEIR THERAPEUTIC USE
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63152309A (en) * 1986-08-11 1988-06-24 Lion Corp External preparation of skin
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE3733017A1 (en) 1987-09-30 1989-04-13 Bayer Ag Stilbene synthase gene
US5689046A (en) 1987-09-30 1997-11-18 Bayer Aktiengesellschaft Stilbene synthase gene
DE58905201D1 (en) * 1988-03-01 1993-09-16 Birkmayer Walther AGENT FOR TREATING THE PARKINSON SYNDROME.
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE4107396A1 (en) * 1990-06-29 1992-01-02 Bayer Ag STYLE SYNTHASE GENES FROM VINEYARD
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
JP3214049B2 (en) 1992-03-09 2001-10-02 史衛 佐藤 Method for producing cis-olefin
DE4232899C2 (en) * 1992-09-30 1995-02-23 Birkmayer Joerg Univ Prof Dr Use of NADH and NADPH to treat Alzheimer's disease
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
WO1995002697A1 (en) 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6048903A (en) * 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
DE69535178T2 (en) 1994-06-10 2006-12-14 Genvec, Inc. ADENOVER VECTOR SYSTEMS AND CELL LINES
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
JP3565859B2 (en) 1994-10-28 2004-09-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Improved adenovirus and uses thereof
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
DE4440200A1 (en) * 1994-11-10 1996-05-15 Bayer Ag DNA sequences and their use
NZ300387A (en) 1994-12-12 2001-07-27 Genetic Therapy Inc Adenoviral vector modified to reduce host immune and inflammatory responses and its use in gene therapy treatment
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
WO1996026285A2 (en) 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methods and compositions for administering gene therapy vectors
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6143548A (en) 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
IT1276225B1 (en) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR
FR2741238B1 (en) * 1995-11-17 2001-11-30 Goemar Lab Sa USE OF ALUMINUM CHLORIDE AS AN ELICITOR OF RESVERATROL SYNTHESIS
US6124125A (en) * 1996-01-08 2000-09-26 Trustees Of Dartmouth College AMP activated protein kinase
DE19624668A1 (en) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Use of pyridylalkane, pyridylalken or pyridylalkynamides
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
FR2766176B1 (en) * 1997-07-15 1999-10-29 Caudalie COMPOSITIONS BASED ON RESVERATROL DERIVATIVES
US6270780B1 (en) * 1997-07-25 2001-08-07 Chesebrough-Pond's Usa Co., Division Of Conopco Cosmetic compositions containing resveratrol
BR9803596A (en) * 1997-09-23 2000-04-25 Pfizer Prod Inc Derivatives of resorcinol.
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6008260A (en) 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
AT407821B (en) * 1998-03-24 2001-06-25 Franz Dr Stueckler MEDIUM BASED ON NATURAL SUBSTANCES
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6448450B1 (en) * 1998-05-08 2002-09-10 Calyx Therapeutics, Inc. 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment
US6245814B1 (en) * 1998-05-08 2001-06-12 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6624197B1 (en) * 1998-05-08 2003-09-23 Calyx Therapeutics, Inc. Diphenylethylene compounds
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
ATE324105T1 (en) 1998-09-08 2006-05-15 Cornell Res Foundation Inc USE OF CYCLOOXYGENASE-2 INHIBITORS TO TREAT INFLAMMATORY DISEASES OF THE HEAD AND NECK
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
IT1302365B1 (en) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US6361815B1 (en) * 1998-12-21 2002-03-26 Pure World Botanicals, Inc. Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
US6190716B1 (en) * 1999-02-17 2001-02-20 Scott O. Galbreath, Jr. Method for preparing a grape derived product
FR2790645B1 (en) 1999-03-12 2001-06-08 Arkopharma Laboratoires FOOD SUPPLEMENT AND COSMETIC TREATMENT METHOD BASED ON GRAPE EXTRACT RICH IN POLYPHENOLS
US6878381B2 (en) 1999-03-22 2005-04-12 Pfizer, Inc Resorcinol composition
EP1169647B1 (en) * 1999-04-12 2007-06-20 Sumitomo Chemical Company, Limited Method for analyzing the amount of intraabdominal adipose tissue
FR2795643B1 (en) * 1999-07-02 2004-06-11 Oreal FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID
ATE281179T1 (en) 1999-08-13 2004-11-15 Univ Maryland Biotech Inst COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS THEREOF
ES2322328T3 (en) * 1999-09-03 2009-06-19 Sigma-Tau Healthscience S.P.A. L-CARNITINE ULTRAFINA, PREPARATION PROCEDURES, COMPOSITIONS CONTAINING IT AND PROCEDURE FOR THE SAME USE.
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU7596100A (en) * 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6358517B1 (en) * 1999-10-22 2002-03-19 Unilever Home & Personal Care Usa, Division Of Conopco Cosmetic compositions containing resveratrol and retinoids
US20020002200A1 (en) 2000-02-04 2002-01-03 Bishwagit Nag Novel diphenylethylene compounds
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US6416806B1 (en) * 2000-03-20 2002-07-09 James H. Zhou Herbal caffeine replacement composition and food products incorporating same
WO2001070212A2 (en) 2000-03-23 2001-09-27 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of menopause
IT1318425B1 (en) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro USE OF RESVERATROL FOR THE TREATMENT OF DESQUAMATIVE ECZEMA, ACNE AND PSORIASIS.
IT1317034B1 (en) 2000-05-30 2003-05-26 Istituto Di Medicina Speriment METHOD OF EXTRACTION OF PHARMACEUTICAL ACTIVITY PRODUCTS FROM PLANTS SPERMATOPHYTES, PRODUCTS SO OBTAINED AND THEIR USE IN MEDICINE, IN
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
ITNA20000036A1 (en) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF DANDRUFF.
ITNA20000037A1 (en) 2000-06-02 2001-12-02 Dev Biotechnological Proces Se INNOVATIVE MULTIFUNCTION SOLAR FILTER.
IT1318565B1 (en) 2000-06-09 2003-08-27 World Pharma Tech Ltd NADH OCTOCOSANOL EVITAMIN E PROENERGETIC FOOD SUPPLEMENT
US6795856B1 (en) 2000-06-28 2004-09-21 Accountability International, Inc. System and method for monitoring the internet access of a computer
US20020120008A1 (en) * 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US6319523B1 (en) 2000-06-29 2001-11-20 James H. Zhou Composition and method for inhibiting oral bacteria
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
DE10034320A1 (en) * 2000-07-14 2002-02-07 Inst Pflanzenbiochemie Ipb Process for influencing the sinapine content in transgenic plant cells and plants
FR2812195B1 (en) * 2000-07-28 2003-07-11 Oreal TOPICAL APPLICATION COMPOSITIONS COMPRISING GLUCOSYLATED HYDROXYSTILBENES AND UTILIZATIONS
US20020110604A1 (en) * 2000-08-11 2002-08-15 Ashni Naturaceuticals, Inc. Composition exhibiting synergistic antioxidant activity
US6552085B2 (en) * 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US6541522B2 (en) * 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
WO2002039956A2 (en) * 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
US20030165854A1 (en) * 2000-12-05 2003-09-04 Cunningham Mary Jane Marker genes responding to treatment with toxins
US20030082647A1 (en) * 2000-12-12 2003-05-01 Reenan Robert A. Transporter protein
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
WO2004096256A1 (en) 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US20030190381A1 (en) 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
FR2820320B1 (en) * 2001-02-02 2003-04-04 Oreal SUSPENSION OF LIPOPHILIC ACTIVE INGREDIENT NANOSPHERES STABILIZED BY WATER-DISPERSIBLE POLYMERS
US20020146424A1 (en) * 2001-02-20 2002-10-10 Benza Raymond L. Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
US6300377B1 (en) * 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
ITPI20010014A1 (en) * 2001-03-05 2002-09-05 Ivo Pera COMPOUND FOR FILTERS FOR CIGARETTES, OR OTHER SMOKING ITEMS, BASED ON ANTIOXIDANT SUBSTANCES AND THE FILTER SO OBTAINED
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
US20030044946A1 (en) * 2001-04-03 2003-03-06 Longo Valter D. Genes, mutations, and drugs that increase cellular resistance to damage and extend longevity in organisms from yeast to humans
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US20030180719A1 (en) * 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
US20030004142A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6426061B1 (en) * 2001-04-20 2002-07-30 Weiwei Li Method and composition for preventing sweat-related odor
WO2002089790A1 (en) 2001-05-03 2002-11-14 Cornell Research Foundation, Inc. Treatment of hpv caused diseases
US6368617B1 (en) * 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
CN1398838A (en) 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 Diphenylethylene compound and its prepn and application in preventing and treating diabetes
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
US7396546B2 (en) 2001-08-06 2008-07-08 The Quigley Corporation Anti-microbial compositions and methods of using same
US20030082597A1 (en) * 2001-08-15 2003-05-01 Cannon L. Edward Age-associated markers
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
US6680342B2 (en) * 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
US6656969B2 (en) * 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20030055114A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
CA2461099A1 (en) * 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US20030082116A1 (en) * 2001-09-28 2003-05-01 Closure Medical Corporation Adhesive compositions containing dual function stabilizers and active agents
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
EP1304161B1 (en) * 2001-10-19 2007-02-28 Pacific Corporation Thermotropic liquid crystal polymer microcapsules, a method for preparing the same, and cosmetic compositions containing the same
ATE276676T1 (en) * 2001-10-22 2004-10-15 Ivo Pera COMPOSITION FOR REDUCING OR CANCELING NICOTINE DEPENDENCE
US6767563B2 (en) * 2001-10-30 2004-07-27 Michael D. Farley Immune functions
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
EP1453848A4 (en) * 2001-11-21 2009-09-09 Einstein Coll Med Sir2 products and activities
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition
FR2832630B1 (en) * 2001-11-28 2005-01-14 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE OXIDATION-SENSITIVE HYDROPHILIC ACTIVE STABILIZED WITH AT LEAST ONE COPOLYMER OF N-VINYLIMIDAZOLE
US20030118617A1 (en) * 2001-12-21 2003-06-26 Avon Products, Inc. Resveratrol analogues
NZ516366A (en) * 2001-12-24 2004-07-30 Enzo Nutraceuticals Ltd Increased lifespan formulation using pine bark flavonoid extract
WO2003058503A1 (en) * 2001-12-26 2003-07-17 The Regents Of The University Of California System and method for identifying networks of ternary relationships in complex data systems
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
CA2478997C (en) 2002-03-08 2013-12-17 Protemix Corporation Limited Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
US20030199581A1 (en) 2002-03-13 2003-10-23 Seligson Allen L. Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US6777392B2 (en) 2002-03-28 2004-08-17 Council Of Scientific And Industrial Research 8-(C-β-D-glucopyranosyl)-7, 3', 4'-trihydroxyflavone, process of isolation thereof, pharmaceutical composition and method for the treatment of diabetes
US20030224077A1 (en) 2002-04-08 2003-12-04 Societe L'oreal S.A. Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
EP1496880A4 (en) * 2002-04-24 2007-12-12 Res Dev Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
WO2003094833A2 (en) * 2002-05-10 2003-11-20 Orchid Chemicals & Pharmaceuticals Limited A new stereoselective route to produce tris-o-substituted-(e)-( 3,5-dihydroxyphenyl)-2-(4- hydroxyphenyl)ethene
WO2003104403A2 (en) 2002-06-07 2003-12-18 Wisconsin Alumni Research Foundation Method of controling acetylation of metabolic enzymes
JP2005533042A (en) 2002-06-10 2005-11-04 オクラホマ　メディカル　リサーチ　ファウンデーション Methods for using linked bis (polyhydroxyphenyl) and its O-alkyl derivatives in the treatment of inflammatory conditions of the central nervous system
DE10230961A1 (en) 2002-07-10 2004-02-12 Lorenz, Peter, Dr. Use of hydroxyresveratrol or a mulberry extract to prepare a neuroprotective agent for preventing or treating diseases of the central and peripheral nervous systems
AU2003242965B2 (en) * 2002-07-11 2009-02-05 Dermipsor Ltd. Composition and methods for the treatment of skin disorders
WO2004009539A2 (en) 2002-07-19 2004-01-29 Orchid Chemicals And Pharmaceuticals Limited Method for the conversion of a z-isomer into e-isomer
DE10244282A1 (en) 2002-09-23 2004-04-01 Merck Patent Gmbh Preparation with antioxidant properties
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
CN103211806B (en) 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 Novel nutraceutical composition and uses thereof
EP1648437A2 (en) 2003-07-01 2006-04-26 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20050004052A1 (en) * 2003-07-03 2005-01-06 Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
WO2005002527A2 (en) 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
US20050038125A1 (en) * 2003-08-15 2005-02-17 Smit Hobbe Friso Method for the treatment of arthritis and pain
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
WO2005026112A2 (en) 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
DE502004006574D1 (en) * 2004-06-03 2008-04-30 Balcke Duerr Gmbh Hydraulic expansion method and device therefor
PT3006040T (en) * 2004-06-04 2018-03-28 Univ Washington Methods and compositions for treating neuropathies
ZA200701725B (en) 2004-09-24 2008-06-25 Bayer Bioscience Nv Stress resistant plants
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
AU2007229005B2 (en) 2006-03-21 2012-05-31 Bayer Cropscience Nv Stress resistant plants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016726A2 (en) * 2002-08-09 2004-02-26 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON R M ET AL: "MANIPULATION OF A NUCLEAR NAD+ SALVAGE PATHWAY DELAYS AGING WITHOUT ALTERING STEADY-STATE NAD+ LEVELS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 21, 24 May 2002 (2002-05-24), pages 18881 - 18890, XP007900540, ISSN: 0021-9258 *
BLANDER G ET AL: "THE SIR2 FAMILY OF PROTEIN DEACETYLASES", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 73, 2004, pages 417 - 435, XP001206836, ISSN: 0066-4154 *

Also Published As

Publication number Publication date
ES2401342T3 (en) 2013-04-18
AU2006212770A1 (en) 2006-08-17
US20050267023A1 (en) 2005-12-01
JP2012176962A (en) 2012-09-13
WO2006086454A2 (en) 2006-08-17
CA2595495A1 (en) 2006-08-17
EP1851240A2 (en) 2007-11-07
CA2595495C (en) 2014-12-09
AU2006212770B2 (en) 2013-04-04
US7977049B2 (en) 2011-07-12
US20120022013A1 (en) 2012-01-26
EP1851240B1 (en) 2012-12-12
JP2008529502A (en) 2008-08-07
JP2015180657A (en) 2015-10-15

Similar Documents

Publication Publication Date Title
WO2006086454A3 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004016726A3 (en) Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2006015209A3 (en) Differentiation of stem cells
WO2007008758A3 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
WO2007059007A3 (en) Markers of definitive endoderm
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2006044480A3 (en) Nematode resistant transgenic plants
WO2007087153A3 (en) Cyst nematode resistant transgenic plants
TW200733453A (en) Method of using an electrochemical cell
WO2007118242A3 (en) Identification of a constitutively resistant cancer stem cell
WO2008066655A3 (en) Assessment of oocyte competence
WO2005113749A3 (en) Stem cell populations and methods of use
WO2006015887A3 (en) Modulation of alkaloid biosynthesis in plants and plants having altered alkaloid biosynthesis
WO2006088867A3 (en) Method for expansion of stem cells
WO2003022032A3 (en) Method for increasing stress tolerance in plants
WO2008143884A3 (en) Media and devices for cold storage of therapeutic cells
WO2007143204A8 (en) Compositions and methods for modifying cell surface glycans
WO2006032707A3 (en) Plant cells and plants with increased tolerance to environmental stress
WO2008147536A8 (en) Methods and compositions for enhancing proteasome activity
WO2009143421A3 (en) Methods for promoting fusion and reprogramming of somatic cells
WO2006031591A3 (en) Methods and kits for isolating sperm cells
WO2010120541A3 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2003093411A3 (en) Ice1, a regulator of cold induced transcriptome and freezing tolerance in plants
WO2002068635A3 (en) Methods of inhibiting expression of a target gene in mammalian cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2595495

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006212770

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007554337

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006212770

Country of ref document: AU

Date of ref document: 20060208

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006734562

Country of ref document: EP